Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR5 | O14804 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | PCNA | P12004 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13886677 | 0.86 | TAAR5 (0.43) | TAAR5TAAR1ALDH1A1GAAGFER | |
| SCHEMBL17141553 | 0.85 | TAAR5 (0.63) | TAAR5TAAR1PCNAGAANR1I2 | |
| SCHEMBL5742819 | 0.84 | TAAR5 (0.59) | TAAR5TAAR1PCNANR1I2PPARG | |
| SCHEMBL27293661 | 0.83 | TAAR5 (0.66) | TAAR5TAAR1PCNANR1I2PPARG | |
| SCHEMBL5741869 | 0.83 | PCNA (0.62) | PCNAHSP90AB1PPARG | |
| SCHEMBL5098708 | 0.81 | GAA (0.51) | ALDH1A1GAAGFERHSP90AB1MEN1 | |
| SCHEMBL12866370 | 0.79 | NR1I2 (0.62) | TAAR5TAAR1PCNAALDH1A1NR1I2 | |
| SCHEMBL13886734 | 0.77 | TAAR5 (0.68) | TAAR5TAAR1PCNAALDH1A1GFER | |
| SCHEMBL4108699 | 0.76 | GAA (0.66) | PCNAALDH1A1GAAGFERHSP90AB1 | |
| SCHEMBL3858898 | 0.76 | GAA (0.61) | ALDH1A1GAAGFERHSP90AB1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383729-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20040267015-A1 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-12-30 | — | — | US | disclosed |
| EP-1383729-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002081426-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267015-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | TAAR5 4186/4885TAAR1 4309/4885PCNA 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.